CYTOAltamira Therapeutics Ltd.

Nasdaq altamiratherapeutics.com


$ 0.75 $ -0.01 (-1.33 %)    

Wednesday, 18-Sep-2024 11:25:23 EDT
QQQ $ 471.45 $ -3.11 (-0.66 %)
DIA $ 416.43 $ -0.47 (-0.11 %)
SPY $ 562.08 $ -1.78 (-0.32 %)
TLT $ 99.67 $ -0.65 (-0.65 %)
GLD $ 235.64 $ -2.55 (-1.07 %)
$ 0.7601
$ 0.75
$ 0.80 x 350
-- x --
$ 0.75 - $ 0.75
$ 0.73 - $ 17.20
27,775
na
1.12M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 altamira-therapeutics-reports-pricing-of-up-to-12m-public-offering-4m-upfront-with-up-to-additional-8m-of-aggregate-gross-proceeds-upon-exercise-of-milestone-linked-warrants

The company announced the pricing of a public offering of an aggregate of 5.55 million common shares (or pre-funded warrants in...

 altamira-therapeutics-expands-bentrio-license-and-distribution-agreement-with-nuance-pharma-in-east-and-south-east-asia

Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed reque...

 altamira-therapeutics-extends-bentrio-distribution-agreement-with-pharma-nordic-to-include-sweden-and-denmark

Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024 Exclusive distribution agreement extended to also include Sw...

 altamira-therapeutics-zbtb46-mrna-nanoparticles-show-significant-tumor-growth-reduction-and-long-term-remission-when-combined-with-anti-pd1-therapy

Results Published In Nature Immunology Highlight Potential To Enhance Effectiveness Of Immune Checkpoint Inhibitors

 altamira-therapeutics-publishes-preclinical-data-for-treatment-of-abdominal-aortic-aneurysm-with-sod2-mrna-delivered-by-semaphore-nanoparticles

 Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdomi...

 whats-going-on-with-altamira-therapeutics-stock

Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial w...

 altamira-therapeutics-announces-publication-of-results-from-bentrio-trial-in-seasonal-allergic-rhinitis-in-peer-reviewed-journal

Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journalStudy met ...

 altamira-therapeutics-fy-eps-1647-sales-28447k-down-from-33037k-yoy

Altamira Therapeutics (NASDAQ:CYTO) reported quarterly losses of $(16.47) per share. This is a 97.38 percent increase over loss...

 earnings-scheduled-for-april-10-2024

Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share ...

 nasdaq-turns-higher-akanda-shares-plunge

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0....

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION